1-3 of 3
Barry K. Moser, Ph.D.
Close
Sort by
Journal Articles

Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission: Results From North American Leukemia Intergroup Trial C9710

Bayard L. Powell, MD, Barry K Moser, Ph.D., Wendy Stock, MD, Robert E. Gallagher, MD, Cheryl L Willman, MD, Richard M. Stone, MD, Jacob M. Rowe, MD, Steven E. Coutre, MD, James H. Feusner, M.D., John Gregory, MD, Stephen Couban, MD, FRCPC, Frederick R. Appelbaum, MD, Martin S. Tallman, MD, Richard A. Larson, MD
Journal: Blood
Blood (2011) 118 (21): 258.
https://doi.org/10.1182/blood.V118.21.258.258
Published: 2011
Journal Articles

Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60–75 Years: Cancer and Leukemia Group B (CALGB) Study 10502

Eyal C Attar, M.D., Kathleen A. Donohue, M.A., Philip C. Amrein, MD, Martha Wadleigh, MD, Daniel J DeAngelo, MD, PhD, Jonathan E Kolitz, MD, Bayard L. Powell, MD, Peter M Voorhees, M.D., Eunice S. Wang, MD, William Blum, MD, Allison Booth, Richard M Stone, M.D., Barry K Moser, Ph.D., Richard Larson, M.D.
Journal: Blood
Blood (2010) 116 (21): 331.
https://doi.org/10.1182/blood.V116.21.331.331
Published: 2010
Journal Articles

Frequent PML-RAR α Mutations in Relapse Patients on Acute Promyelocytic Leukemia (APL) Intergroup Phase III Trial C9710.

Robert E. Gallagher, MD, Esther L. Schachter-Tokarz, B.A., Barry K. Moser, Ph.D., Dorie Sher, B.A., Elisabeth Paietta, Ph.D., Martin S. Tallman, M.D., Clara D. Bloomfield, M.D., Bayard L. Powell, M.D., Richard A. Larson, M.D., Frederick R. Appelbaum, M.D., Cheryl L. Willman, M.D., Richard C. Harvey, Ph.D., Wendy Stock, M.D.
Journal: Blood
Blood (2006) 108 (11): 2342.
https://doi.org/10.1182/blood.V108.11.2342.2342
Published: 2006